SLGL - Sol-Gel Technologies Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.39
+0.15 (+2.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.24
Open6.26
Bid1.05 x 800
Ask10.59 x 800
Day's Range6.25 - 6.50
52 Week Range6.03 - 16.48
Volume7,732
Avg. Volume14,177
Market Cap121.09M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-3.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.40
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo

    Under the terms of the agreement, Perrigo will conduct the regulatory, scientific, clinical and technical activities necessary to develop the generic product candidate and seek regulatory approval with the U.S Food and Drug Administration (“FDA”). If approved by the FDA, Perrigo has agreed to commercialize the generic product candidate in the United States.

  • GlobeNewswire8 days ago

    Sol-Gel Technologies Reports Second Quarter 2018 Financial Results

    NESS ZIONA, Israel, Aug. 08, 2018-- Sol-Gel Technologies Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...

  • GlobeNewswire2 months ago

    Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea

    Sol-Gel Technologies Ltd. (SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced dosing of the first subject in the pivotal Phase III clinical program evaluating the safety and efficacy of Epsolay® (formerly VERED) in subjects with papulopustular rosacea (also known as subtype II rosacea), a chronic, inflammatory skin condition that most often affects the face. Epsolay is a once-daily topical cream containing encapsulated benzoyl peroxide, 5%, using Sol-Gel’s proprietary microencapsulation technology.

  • GlobeNewswire3 months ago

    Sol-Gel Technologies Announces Participation in Upcoming Investor Conferences

    NESS ZIONA, Israel, May 29, 2018-- Sol-Gel Technologies Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the ...

  • How Do Analysts See Sol-Gel Technologies Ltd (NASDAQ:SLGL) Performing Over The Next Few Years?
    Simply Wall St.4 months ago

    How Do Analysts See Sol-Gel Technologies Ltd (NASDAQ:SLGL) Performing Over The Next Few Years?

    Sol-Gel Technologies Ltd’s (NASDAQ:SLGL) most recent earnings announcement in December 2017 indicated that losses became smaller relative to the prrior year’s level – great news for investors Below is myRead More...